|
1）Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Int Med. 2008; 149: 177-84
|
|
|
|
2）Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010; 137: 952-68
|
|
|
|
|
|
3）Yoshii Y, Kaneko Y, Kinoshita A, et al. The effects of clinical condition of patients with active tuberculosis on the results of the quanntiferon-TB-2G test. Respirology. 2012; 17（Suppl. 2）: 132
|
|
|
|
|
|
4）劉 楷，金子有吾，川本浩徳，他．当院における肺結核症における様々な病態でQuanti FERON TB-3G（QFT-GIT）とT-SPOT.TBの比較検討．結核．2015; 90: 295
|
|
|
|
|
5）Higuchi K, Sekiya Y, Igari H, et al. Comparison of specificities between two interferon-gamma release assays in Japan. Int J Tuberc Lung D. 2012; 16: 1190-2
|
|
|
|
|
|
6）Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J. 2010; 36: 355-61
|
|
|
|
|
|
7）Kobashi Y, Shimizu H, Mouri K, et al. Clinical evaluation of QuantiFERON TB-2G test in patients with healed pulmonary tuberculosis. J Infect Chemother. 2009; 15: 288-92
|
|
|
|
|
|
8）Kaneko Y, Nakayama K, Kinoshita, et al. Relation between recurrence of tuberculosis and transitional changes in IFN-gamma release assays. Am J Respir Crit Care Med. 2015; 191: 480-3
|
|
|
|
|
|
9）日本結核病学会予防委員会・治療委員会．潜在性結核感染症治療指針．結核．2013; 88: 497-512
|
|
|
|
|
|
10）吉山 崇．多剤耐性結核への対策．結核．2013; 88: 749-56
|
|
|
|
|
|
11）Higuchi K, Harada N, Fukazawa, et al. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis. 2008; 88: 244-8
|
|
|
|
|
|
12）Wang S, Diao N, Lu C, et al. Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population. PloS One. 2012; 7: e51338
|
|
|
|
|
|
13）Wergeland I, Pullar N, Assmus J, et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. J Infect. 2015; 70: 381-91
|
|
|
|
|